Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Type II DNA topoisomerases are essential enzymes that manage the topology of DNA by introducing transient double-stranded breaks in the DNA helix. This allows them to resolve tangles, supercoils, knots, and catenanes that arise during vital cellular processes such as replication, transcription, recombination, and chromosome segregation. Type II topoisomerases are major targets for anticancer agents. Drugs like etoposide exploit their mechanism by stabilizing the transient double-strand break intermediate—leading to cytotoxicity especially in rapidly dividing cells such as cancer cells.
Stabilization of the transient double-strand break intermediate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Type II DNA Topoisomerase (None).